HGHéctor Carlos García-Díaz

Héctor Carlos García-Díaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Héctor Carlos García-Díaz has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitals

    by Héctor Carlos García-Díaz, Javier Gómez-Alonso, María Teresa Rabuñal-Álvarez, María Ochagavía, José Luis Revuelta-Herrero, Álvaro González-Gómez, Ana C. Riestra, Aina Oliver-Noguera, María Moreno García, Anna Farriols, et al.

    Patients with pancreatic cancer (PC) harboring DNA damage repair genes (DDRg) alterations, particularly BRCA1/2, may benefit from olaparib. Although the phase III POLO trial demonstrated improved progression-free survival (PFS) with olaparib as maintenance therapy in germline BRCA-mutated metastatic PC, real-world data, especially in patients with non-BRCA DDR alterations, remain limited. The objective of this study is to evaluate the real-world effectiveness and safety of olaparib in PC patients harboring DDRg alterations. A multicenter, retrospective observational study was conducted across eight Spanish hospitals. Adult patients with PC and DDRg alterations who initiated olaparib between December 2018 and October 2022 were included. Data were extracted from electronic medical records. PFS and overall survival (OS) were estimated using the Kaplan-Meier method. Adverse events (AEs) were assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. A total of 24 patients were included, most commonly harboring gBRCA2 (58.3%), sBRCA2 (16.7%) or ATM (16.7%) alterations. Among patients receiving olaparib as maintenance therapy (87.5%), the objective response rate (ORR) was 33.3%, the median PFS was 10.4 months (95% CI, 1.7-19.1) and the median OS was 32.9 months (95% CI, 20.1-45.6). At data cutoff, the OS rate >20 months was 71.4% and >30 months was 42.9%. Grade ≥3 AEs occurred in 16.7% of patients. This multicenter real-world study olaparib showed clinical activity and acceptable safety profile in PC patients harboring DDRg mutations, including those beyond BRCA. Further studies are needed to validate these findings and to better identify patients who may benefit from olaparib, particularly those with non-BRCA mutations.

  • Open Access

    [Translated article] Drug dosing in obese critically ill patients, a literature review

    by Hector Carlos García-Díaz, Pablo Sánchez-Sancho, Pilar Lalueza-Broto, Xavier Nuvials, María Queralt Gorgas-Torner, Laura Doménech-Moral


  • Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case example

    by Héctor Carlos García-Díaz, Simeon Eremiev, Javier Gómez-Alonso, Joel Veas Rodriguez, Anna Farriols, Maria J Carreras, César Serrano

    Objective: To review the evidence of uncommon but fatal adverse event of hyperammonemic encephalopathy by tyrosine kinase inhibitors (TKI) and the possible mechanisms underlying this condition and to describe the case of a patient that developed drug-induced hyperammonemic encephalopathy related to TKI. Data Sources: Literature search of different databases was performed for studies published from 1 January 1992 to 7 May 2023. The search terms utilized were hyperammonemic encephalopathy, TKI, apatinib, pazopanib, sunitinib, imatinib, sorafenib, regorafenib, trametinib, urea cycle regulation, sorafenib, carbamoyl-phosphate synthetase 1, ornithine transcarbamylase, argininosuccinate synthetase, argininosuccinate lyase, arginase 1, Mitogen activated protein kinases (MAPK) pathway and mTOR pathway, were used individually search or combined. Data Summary: Thirty-seven articles were included. The articles primarily focused in hyperammonemic encephalopathy case reports, management of hyperammonemic encephalopathy, urea cycle regulation, autophagy, mTOR and MAPK pathways, and TKI. Conclusion: Eighteen cases of hyperammonemic encephalopathy were reported in the literature from various multitargeted TKI. The mechanism of this event is not well-understood but some authors have hypothesized vascular causes since some of TKI are antiangiogenic, however our literature review shows a possible relationship between the urea cycle and the molecular inhibition exerted by TKI. More preclinical evidence is required to unveil the biochemical mechanisms responsible involved in this process and clinical studies are necessary to shed light on the prevalence, risk factors, management and prevention of this adverse event. It is important to monitor neurological symptoms and to measure ammonia levels when manifestations are detected.


  • Carglumic acid in methylmalonic acidemia: Use of breast milk as an alternative vehicle to water

    by Héctor C. García‐Díaz, Carlos J. Parramón‐Teixidó, Susana Clemente‐Batista, Inés Jiménez‐Lozano, Alicia Montaner‐Ramón, Mireia Del Toro

    Carbaglu® or N-carbamylglutamate (NCG) is not recommended for administration in a vehicle other than water. We aim to report the use of breast milk (BM) as an alternative vehicle in a neonate rejecting NCG diluted in water. A neonate diagnosed with methylmalonic acidemia presented symptomatology of acidemia and hyperammonemia. After the patient refused oral NCG administration, a dissolution test was conducted in BM showing correct dissolution. The NCG-BM solution was tolerated and plasma ammonium concentrations remained within range in subsequent analytical controls. BM as a vehicle for NCG is a safe and effective option for patients who refuse suspension in water and could lead to better treatment compliance in paediatric patients.